Covalent Modification: Chemical Biology and Therapeutic Applications
Deadline Sep 17 2021 11:59 PM (EDT)
Description

Event Date: November 9, 2021
Deadline to Submit Abstracts: September 17, 2021

This application is for a virtual Poster Presentation. Poster submissions may also be considered for Short Talks. See here for submission guidelines.

Covalent target modulation is reemerging as a promising strategy to identify novel therapeutic mechanisms and to drug “tough” targets. Technological advance in proteomics have opened the door to a wider range of targetable residues and set the stage for rational design of covalent modifiers.  For example, the development of the KRAS G12C covalent inhibitor has heralded a new paradigm for these agents. This symposium will convene a diverse group of academic and industry scientists from the fields of medicinal chemistry, chemical biology, proteomics and pharmacology to discuss the latest research in the design of covalent libraries and new warheads, addressing intrinsic reactivity of ligands and their relationship to promiscuousness, deconvolution of hits emerging from phenotypic screens, warhead PK tolerance and identification of novel targets in human disease context to name a few. This symposium will empower attendees to think boldly about covalent inhibitors for intractable targets and build confidence in initiating successful covalent screening campaigns, further the ground-breaking work of the speakers and gain confidence in clinical translation of covalent molecules.

To register for this event, please visit the main website at: https://www.nyas.org/covalent2021

Covalent Modification: Chemical Biology and Therapeutic Applications


Event Date: November 9, 2021
Deadline to Submit Abstracts: September 17, 2021

This application is for a virtual Poster Presentation. Poster submissions may also be considered for Short Talks. See here for submission guidelines.

Covalent target modulation is reemerging as a promising strategy to identify novel therapeutic mechanisms and to drug “tough” targets. Technological advance in proteomics have opened the door to a wider range of targetable residues and set the stage for rational design of covalent modifiers.  For example, the development of the KRAS G12C covalent inhibitor has heralded a new paradigm for these agents. This symposium will convene a diverse group of academic and industry scientists from the fields of medicinal chemistry, chemical biology, proteomics and pharmacology to discuss the latest research in the design of covalent libraries and new warheads, addressing intrinsic reactivity of ligands and their relationship to promiscuousness, deconvolution of hits emerging from phenotypic screens, warhead PK tolerance and identification of novel targets in human disease context to name a few. This symposium will empower attendees to think boldly about covalent inhibitors for intractable targets and build confidence in initiating successful covalent screening campaigns, further the ground-breaking work of the speakers and gain confidence in clinical translation of covalent molecules.

To register for this event, please visit the main website at: https://www.nyas.org/covalent2021

Deadline
Sep 17 2021 11:59 PM (EDT)